Fosun Pharma announces LP change in fund, drug filing accepted

Shanghai Fosun Pharmaceutical Group has announced an update regarding its participation in the Dalian Star Future Fund, a private equity investment fund. Dalian Rongda, a previous limited partner, will transfer its subscribed capital of 145 million yuan (72.5 million yuan of which is paid-in) to Dalian Jinyun. This change, effective December 2, 2025, sees Dalian Jinyun, a state-owned entity, becoming a new LP. Fosun Pharma's affiliated entities, Dalian Furejian and Ningbo Fuying, maintain their 51% combined stake in the fund, which focuses on early to mid-stage innovative enterprises in medical devices, technology, and related industries.

In a separate development, Fosun Pharma's subsidiary, Shanghai Hanhong Runlian Biotechnology Co., Ltd., has received acceptance from the National Medical Products Administration for its drug registration application for HLX14, a denosumab biosimilar. HLX14, an investigational product with approximately 320 million yuan in cumulative R&D investment, is indicated for all approved uses of its reference product, Prolia, in China.

This biosimilar has already secured approval in the US, EU, and UK, and its marketing authorization application was accepted by Health Canada in September 2024. The commercialization in China is contingent upon further regulatory steps, including GMP compliance checks and final drug registration approval. The company highlighted potential market uncertainties, including demand, competition, and distribution channels.